Celldex presents long─term results from Phase II study of barzolvolimab

Celldex Therapeutics has unveiled groundbreaking long-term results from its Phase 2 study of barzolvolimab, revealing sustained and profound improvements in angioedema for patients suffering from chronic spontaneous urticaria (CSU) that is refractory to standard antihistamines. Presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul this past week, the data showed up to 64% of angioedema-afflicted patients remained symptom-free seven months after discontinuing treatment, signaling a potential paradigm shift from mere symptom control to genuine disease modification. This development holds significant implications for the estimated 55% of CSU patients whose lives are severely impacted by angioedema, a debilitating swelling that current treatments often fail to address adequately. Barzolvolimab, a novel monoclonal antibody, targets the KIT receptor, thereby inhibiting the aberrant activity of mast cells, which are the root cause of these inflammatory responses. With these robust Phase 2 outcomes, Celldex's ongoing, industry-largest Phase 3 trials in CSU are now further bolstered, along with parallel Phase 3 programs initiated for other mast cell-mediated conditions like cold urticaria and symptomatic dermographism. Investors and medical professionals alike will be keenly watching for topline data from these pivotal Phase 3 trials, anticipated in the fourth quarter of 2026. Should these results mirror the sustained efficacy seen in Phase 2, barzolvolimab could redefine the treatment landscape for chronic urticarias, offering a disease-modifying option where only symptomatic relief often exists. Celldex, having recently completed a public offering to fund its pipeline through 2028, is now positioned for a critical period that could validate its mast cell-centric therapeutic strategy and unlock substantial market value.